Ignite Creation Date:
2025-12-25 @ 3:16 AM
Ignite Modification Date:
2026-02-03 @ 12:06 PM
Study NCT ID:
NCT04681105
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-12-31
First Post:
2020-12-01
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
Sponsor:
City of Hope Medical Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Recurrent Acute Leukemia | View |
| None | Recurrent B Acute Lymphoblastic Leukemia | View |
| None | Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm | View |
| None | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | View |
| None | Recurrent Hairy Cell Leukemia | View |
| None | Recurrent Hematologic Malignancy | View |
| None | Recurrent Hodgkin Lymphoma | View |
| None | Recurrent T Acute Lymphoblastic Leukemia | View |
| None | Refractory Acute Leukemia | View |
| None | Refractory B Acute Lymphoblastic Leukemia | View |
| None | Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm | View |
| None | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | View |
| None | Refractory Hairy Cell Leukemia | View |
| None | Refractory Hematologic Malignancy | View |
| None | Refractory Hodgkin Lymphoma | View |
| None | Refractory T Acute Lymphoblastic Leukemia | View |
| None | Systemic Mastocytosis | View |
Keywords: